<DOC>
	<DOCNO>NCT02652936</DOCNO>
	<brief_summary>This 2-part , single centre , single ( Part 1 ) multiple ( Part 2 ) dose escalation study healthy male subject .</brief_summary>
	<brief_title>A Pharmacokinetics Study AF-130 Healthy Subjects</brief_title>
	<detailed_description>Part 1 double-blind , placebo-controlled , randomised single dose design 64 healthy male subject . Part 1 consist Groups 1 6 , comprise 8 subject ( total 48 subject ) . There option enrol 2 additional group ( 8 subject Groups 7 8 ) ass alternative dose level . Subjects randomise receive active placebo fast state . Part 2 double-blind , placebo-controlled , randomise , multiple ascend dose design 45 healthy male subject . Part 2 consist Groups 9 11 , comprise 9 subject ( total 27 subject ) . There option enrol 2 additional group ( 9 subject Groups 12 13 ) ass alternative multiple dose level . Part 2 commence completion Groups 1 3 Part 1 . Subjects randomise receive active placebo fast state . The planned dose regimen per day however , may modify twice per day depend emerge pharmacokinetic data Part 1 .</detailed_description>
	<criteria>Healthy male Age 18 55 year Body mass index 18.0 35.0 kg/m2 Willing able communicate participate whole study Must provide write informed consent Must agree use adequate method contraception Participation clinical research study within previous 3 month Subjects study site employee , immediate family member study site sponsor employee Subjects previously enrol study History drug alcohol abuse past 2 year Regular alcohol consumption &gt; 21 unit per week ( 1 unit = Â½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screen Subjects suitable vein multiple venepunctures/cannulation Clinically significant abnormal biochemistry , haematology urinalysis Positive drug abuse test result Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result History cardiovascular , renal , hepatic , chronic respiratory gastrointestinal disease judge investigator QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 m screen predose Gastric intestinal surgery , except fully heal appendectomy and/or cholecystectomy Serious adverse reaction serious hypersensitivity drug formulation excipients Presence history clinically significant allergy require treatment Ingestion grapefruit grapefruit juice within 48 h dose administration Donation loss great 400 mL blood within previous 3 month Subjects take , take , prescribed overthecounter drug ( 4 g per day paracetamol ) herbal remedy 14 day study drug administration Receipt investigational product device , participation drug research study within period 30 day ( 5 halflives , whichever long ) first dose study medication Receipt investigational immunomodulator monoclonal antibody within 180 day ( 5 halflives , whichever long ) first dose study medication Failure satisfy investigator fitness participate reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>